Are you looking for an answer to the topic “Moncef Slaoui Bio, Age, Wife, GSK, Coronavirus, Operation Warp Speed, Net worth“? We answer all your questions at the website Abettes-culinary.com in category: Top 4620 tips from Abettes-culinary update new. You will find the answer right below.
Keep Reading
Dr. Moncef Slaoui Biography
Moncef Slaoui is an immunologist who served as GlaxoSmithKline’s former Present of Vaccines and Head of Pharmaceutical Research and Development. In May 2020, he was appointed by Present Donald Trump to be the chief adviser on Operation Warp Speed, the government’s effort to expedite development of a vaccine for the coronavirus.
Moncef Slaoui Age
Moncef was born on July 27, 1959 in Agadir, Morocco.
Moncef Slaoui Nationality
Moncef is a Moroccan, Belgian and American citizen.
Moncef Slaoui Education
Slaoui holds a Ph.D. in Molecular Biology and Immunology from the Université Libre de Bruxelles in Belgium. He holds PhDs from Harvard Medical School and Tufts University School of Medicine in Boston.
Moncef Slaoui Wife
dr Moncef is married to Kristen E. Belmonte Slaoui, Vice Present and Head of Business Development for GlaxoSmithKline’s (GSK) Commercial Portfolio. She joined GSK’s business development team in 2006. She previously worked in respiratory drug discovery.
She graduated from Gettysburg College with a bachelor’s degree in biology and ical studies. She earned a Ph.D. in physiology from the Johns Hopkins Bloomberg School of Public Health. She completed an NIH Post-Doctoral Fellowship at the University of Washington.
Moncef Slaoui Immunologist
Moncef is an immunologist. He was Professor of Immunology at the University of Mons, Belgium and has authored more than 100 scientific papers and presentations.
Dr. Moncef Slaoui Vaccine
Moncef has a passion for vaccine development as it is personal to him. His sister died of whooping cough, an immunizable disease, while growing up in Morocco. He is credited with a vaccine against cervical cancer and pneumococcal immunization. In 2015 he received European approval for the world’s first malaria vaccine.
Moncef Slaoui GSK
Moncef is a former Chairman of GlaxoSmithKline (GSK) Global Vaccines and Head of Pharmaceutical Research and Development. He joined the company in 1988 as a laboratory scientist.
He also served on the Board of Directors for 11 years and led global pharmaceutical R&D activities from 2006 to 2015. His previous roles have included Chairman of Global R&D and Vaccines, Chairman of R&D and Senior Vice Present of Global Business Development and External Alliances.
Between 2006 and 2015 he served as Chairman of GSK’s Pipeline Investment Board
(PIB) and was Director of GSK from 2006 to 2017. He is also CEO of Galvani, a bioelectronics-focused biotechnology company co-owned by GSK and Verily, an Alphabet
Company.
dr Slaoui previously served on the Singapore Agency for Science, Technology and Research (A*STAR) Advisory Board and on the Advisory Committee of the Director of the National Institutes of Health (NIH). He is currently a member of the Advisory Board of the Qatar Foundation.
Moncef Slaoui Moderna
dr Moncef has served on Moderna’s board of directors since 2017. He resigned in May 2020 after being appointed by Present Donald Trump to lead the White House’s Operation Warp Speed Initiative. Moderna, Inc. is a clinical-stage biotechnology company developing breakthrough messenger RNA (mRNA) therapeutics and vaccines to deliver a new generation of transformative medicines for patients.
Moncef sa he values his time as a board member and wishes the company well. “I am honored to have been asked by the administration to take on this important responsibility. My entire professional career has been focused on developing therapies and vaccines that benefit many. I was inspired by Moderna’s vision to invest in the development of a new of messenger RNA-based drugs and vaccines. I have greatly appreciated my time as a board member and I wish the company well as it continues on its mission for patients.”
Noubar Afeyan, Moderna’s co-founder and chairman, wished him well as he left the company; “I would like to thank Moncef for his critical insight and three years of service on the Moderna board. “Moncef’s comprehensive guance on vaccine and therapeutic development has been important as we continue to advance Moderna’s mRNA platform. We wish him all the best in this new role.”
Stéphane Bancel, Chief Executive Officer of Moderna, sa: “I appreciate Moncef’s contribution to Moderna’s Board of Directors in his role as Chair of the Product Development Committee. His expertise and skills have been invaluable as we approach advanced stages of development in our clinical programs. It has been a privilege to work with Moncef for the past three years.”
Moncef Slaoui Coronavirus
In March 2020, Morocco World News reported that in a statement to Moroccan French-language newspaper L’Economiste, Moncef denied that he was part of a US government task force to find a vaccine against COVID-19.
He sa that he is a member of Moderna’s Research and Development Board. The committee has received support from federal organizations to fund the development of a COVID-19 vaccine
“Moderna, which has a very advanced technological platform, between January 13, the date of receiving the DNA sequence of the virus, and March 25, was able to design and manufacture the vaccine in such a way that it can be injected into humans. We will be sure of its protective potential in the coming months. By the end of the year we’ll probably know if it works and we’ll be able to produce it.”
Moncef Slaoui Operation Warp Speed
dr Moncef was appointed by Present Donald Trump in May 2020 to lead Operation Warp Speed, the government’s effort to speed up development of a vaccine for the coronavirus. He will serve as Chief Advisor while Gustave F. Perna will serve as Chief Operating Officer.
Present Trump ordered the establishment of the Warp Speed program to try to speed up development of a vaccine that some of his top public health advisers have repeatedly warned may not have an effective vaccine for another 18 months, and perhaps even longer for one we distribution could be ready.
The Warp Speed program is designed to ignite an already robust race to find a vaccine involving several of the largest pharmaceutical companies and a handful of government agencies tasked with spurring innovation among private companies at a time of national crisis.
Moncef Slaoui Net worth
Moncef has an estimated net worth of $3 million.
Chief science adviser to Operation Warp Speed Moncef Slaoui (Full Stream 12/1)
[su_youtube url=”https://www.youtube.com/watch?v=OkK50ibO2iA”]
Images related to the topicChief science adviser to Operation Warp Speed Moncef Slaoui (Full Stream 12/1)
See some more details on the topic Moncef Slaoui Bio, Age, Wife, GSK, Coronavirus, Operation Warp Speed, Net worth here:
Moncef Slaoui – Wikipedia
Moncef Mohamed Slaoui is a Moroccan-born Belgian-American researcher who served as the Head of Operation Warp Speed (OPWASP) under … Slaoui is the former head of the vaccines department at GlaxoSmithKline …
Source: en.wikipedia.org
Date Published: 3/23/2021
View: 3364
Slaoui will return $3.86M to GlaxoSmithKline after his …
Former Operation Warp Speed chief Moncef Slaoui, who GlaxoSmithKline fired last year because of a sexual harassment claim, is return.
Source: www.fiercepharma.com
Date Published: 4/16/2022
View: 5435
Moncef Slaoui Bio, Age, Wife, GSK, Coronavirus, Operation …
Dr. Moncef Slaoui Biography Moncef Slaoui is an immunologist who served … Moncef Slaoui Bio, Age, Wife, GSK, Coronavirus, Operation Warp Speed, Net worth …
Source: www.650.org
Date Published: 1/22/2022
View: 7238
Operation Warp Speed’s Moncef Slaoui guided COVID-19 …
Meet Moncef Slaoui. As science adviser of Operation Warp Speed, the veteran pharmaceutical executive helped usher a coronavirus vaccine to the …
Source: www.usatoday.com
Date Published: 11/30/2022
View: 5382
Moncef Slaoui
Moroccan-American-Belgian physician and researcher
Moncef Mohamed Slaoui[1] ( ; French: [mɔ̃sɛf slavi]; Moroccan Arabic: منصف السلاوي, IPA: [ˈmonsˤəf ˈsːlæwi]; born July 22, 1959) is a Moroccan-born Belgian-American researcher who served as Operations Manager Warp Speed (OPWASP) under President Donald Trump from 2020 to 2021.
Slaoui is the former Head of Vaccines at GlaxoSmithKline (GSK).[2] He worked for the company for thirty years and retired in 2017. On May 15, 2020, President Donald Trump announced that Slaoui would lead the U.S. government’s development of a vaccine to treat the coronavirus disease OPWASP;[3] Slaoui resigned on January 12, 2021 after successfully supporting the introduction of a range of vaccines to the US and global markets.
Early life and education[edit]
Slaoui was born on July 22, 1959 in Agadir, Morocco.[4] The city was evacuated after an earthquake in February 1960, and Slaoui grew up in Casablanca.[5] His father worked in the irrigation business[6] and died when Slaoui was a teenager, leaving his mother to raise him and his four siblings.[5]
Slaoui graduated from Mohammed V High School in Casablanca. In 1976, at the age of 17, Slaoui left Morocco to study medicine in France, but missed the registration deadline due to new registration procedures and his mother’s illness.[6] He enrolled at the Université libre de Bruxelles, where he received a BS and MS in biology. During this time he was very active politically.[6] In 1983, Slaoui received his doctorate in molecular biology and immunology from the Free University of Brussels.[7][8] His dissertation was entitled Etude de la diversité et de la selection des répertoires idiotypiques dans le système immunitaire. Slaoui’s supervisor was the immunologist Jacques Urbain.[9]
Slaoui completed postgraduate courses at Harvard Medical School and Tufts University School of Medicine[3] without earning degrees.[10] In 1998 he received an accelerated MBA from the International Institute for Management Development (IMD) in Lausanne, Switzerland.[8]
Career [edit]
Slaoui and his wife lived in the United States from 1983 to 1985 while they were postdoctoral fellows at Harvard.[5] When she was recruited to continue influenza research at SmithKline-RIT in Belgium (which later became part of GlaxoSmithKline (GSK)),[6] Slaoui got a job teaching immunology at the University of Mons in Belgium.[11]
Slaoui has co-authored more than 100 research papers.[12]
GlaxoSmithKline[ edit ]
Slaoui (far right) at a GSK event in December 2016
In 1988, after serving as a consultant for SmithKline-RIT for three years, Slaoui joined the company as a vaccine researcher.[5][7] In 2006 he was appointed Head of Research and Development at GlaxoSmithKline, succeeding Tachi Yamada.[13][14] In 2007 he announced plans to establish a neuroscience research group in Shanghai, which would employ a thousand scientists and cost $100 million; it ceased operations in August 2017.[15]
In 2008, Slaoui led the $720 million acquisition of Sirtris Pharmaceuticals, which fell through in 2013 amid turmoil.[16] In 2012, he oversaw GSK’s purchase of Human Genome Sciences for over $3 billion.[16] He “sold GSK’s entire oncology business, which turned Novartis into a ‘cancer heavyweight’.”
Slaoui worked at GSK for thirty years.[3] During his time there, Slaoui oversaw the development of numerous vaccines, including Cervarix to prevent cervical cancer, Rotarix to prevent gastroenteritis in children, and an Ebola vaccine.[12] He also spent 27 years researching a malaria vaccine, Mosquirix, which was approved by the European Medicines Agency in 2015 and touted as the world’s first.[17]
In April 2013, he co-authored a paper with several other GSK chiefs that introduced the term “electroceutics” to broadly encompass medical devices that use electrical, mechanical, or light stimulation to affect electrical signal transmission in relevant tissue types. [18] In the next few years he tried to bring GSK’s development of bioelectronic medicine closer to a public audience by appearing on YouTube[19] and at futuristic conferences[20].
In July 2013, he wrote an op-ed in The Huffington Post titled “It’s Time to Further Incentivize Medical Innovation,” outlining three recommendations for improving the effectiveness of the pharmaceutical industry.[21]
The Slaoui Center for Vaccines Research in Rockville, Maryland—named after Slaoui and GSK’s first research and development facility in the United States—opened on December 14, 2016.[22][23][24]
As of 2016, Slaoui served on the board of the PhRMA lobby.[25]
In 2016, he was appointed to the founding board of directors of Galvani Bioelectronics, the joint venture between GSK and Verily Life Sciences, a subsidiary of Alphabet Corporation.[14]
Slaoui retired from GSK on June 30, 2017.[26]
Corporate Boards[ edit ]
He joined the Moderna board of directors in July 2017.[27]
In September 2017 he joined the European venture capital firm Medicxi.[28]
COVID-19 pandemic and OPWASP [ edit ]
On May 15, 2020, President Donald Trump formally announced OPWASP, a project to develop and deliver 300 million doses of a 2019 coronavirus disease vaccine by January 2021.[3] Slaoui was appointed to lead the project, working with Chief Operating Officer and Four-Star General Gustave F. Perna.[29] Other candidates for Slaoui’s position were reportedly Elias Zerhouni and Arthur Levinson.[11][30] President Trump described Slaoui as “one of the most respected men in the world in the manufacture and indeed in the formulation of vaccines,” while Health Secretary Alex Azar praised him as “arguably the world’s most experienced and successful vaccine developer”.[31]
To avoid a conflict of interest, Slaoui resigned from the board of directors of Massachusetts-based biotech company Moderna, which had developed a vaccine against the coronavirus.[3][32] Slaoui has faced criticism, particularly from Senator Elizabeth Warren, for continuing to hold over $10 million worth of Moderna stock options. On May 18, 2020, Slaoui resigned from the board of manufacturing company Lonza, with which Moderna had partnered to develop a coronavirus vaccine.[35] On May 19, after initially denying a conflict of interest, Slaoui sold his Moderna shares and donated the value gained since May 14 to cancer research.[35][36][37]
On May 20, The New York Times reported that Slaoui had also resigned as an advisor to Brii Biosciences, a firm with significant Chinese investments, and would resign from Artizan Biosciences and Clazado. According to Michael Caputo, Slaoui’s decision to keep his GSK shares, even after he was announced as OPWASP’s chief adviser, was approved by the Department of Health.[38]
Slaoui was scheduled to speak at the annual Biotechnology Innovation Organization (BIO) conference on June 9, 2020, but eventually withdrew for not informing Congress beforehand.[39]
Slaoui resigned from OPWASP on January 12, 2021.[40]
According to OPWASP[ edit ]
On March 24, 2021, Slaoui was fired as CEO of Galvani Bioelectronics – a medical research company largely owned by GSK – over historic allegations of sexual harassment.[41][42][43]
Personal life[edit]
Slaoui is Muslim.[44][45] He is fluent in Arabic, English and French.[12] He is a citizen of Morocco, Belgium and the United States.[46]: 8
Slaoui has three sons[6] and is married to Kristen Slaoui (née Belmonte), a 1992 graduate of Gettysburg College.[46] : 8 Slaoui’s younger sister died of whooping cough at a young age.[5][47] One of his two younger brothers, a pediatrician, Amine, died of pancreatic cancer.[6] His other brother Mohamed is a specialist in gastroenterology and his older sister Hadia is a university professor of French literature in Morocco.[6][5]
Memberships[ edit ]
2006-2015: Global Research & Development of GSK PLC, Chairman [8]
2006-2017: GSK PLC, Board Member [8]
2009-2017: Global Vaccines of GSK PLC, Chairman[8]
Honorary posts[ edit ]
After GSK[ edit ]
Recognition [ edit ]
Gettysburg College awarded Slaoui an honorary Doctor of Science degree in May 2017.[46] In 2012, FierceBiotech named Slaoui one of the “25 Most Influential People in the Biopharmaceutical Industry Today.”[62] In 2016, Fortune ranked him among The World’s 50 Greatest Leaders.[47] The Medicine Maker included Slaoui in its 2018 list of the “World’s Top 100 Medicine Makers”.[63]
Slaoui was named one of the 100 most influential Africans by New African magazine in 2020.[64]
Selected Works and Publications[ edit ]
work [edit]
Author profile for Moncef Slaoui. Scholia has a profile for
Publications[ edit ]
References[edit]
Deliver a safe, effective COVID-19 vaccine in less than a year Impossible. Meet Moncef Slaoui.
PHILADELPHIA — In 2009, a flu pandemic was raging around the world when a venture capital firm that backs healthcare companies was holding its annual retreat. The gathering was a who’s who of pharma and biotechnology executives – the top executives of the top companies in the world.
One man rounded up a group of his ilk and issued a directive: “We will work together to make a difference here.”
This scene came to mind when the Trump administration asked Jeremy Levin, head of the industry’s Biotechnology Innovation Organization, who should lead America’s effort to develop COVID-19 vaccines.
“Moncef Slaoui,” he answered without hesitation.
Slaoui, 61, a Moroccan-born retired vaccine developer and executive at a pharmaceutical company, has brought his colleagues together before, so it seemed logical to tap him again.
Slaoui’s name came up repeatedly in the spring when Health and Human Services Secretary Alex Azar was looking for someone in the private sector to help lead Operation Warp Speed – an unprecedented and bold effort to have a COVID-19 vaccine by the end of the year to provide.
The scientific community was among the skeptics. The fastest vaccine development ever was for mumps and took four years. Many said there was no way to produce a safe, effective vaccine in seven months. Something would have to be compromised.
Slaoui thought he could do it.
In many ways he had been preparing for this challenge all his life.
A political activist in his youth, he spent nearly 30 years at pharmaceutical giant GlaxoSmithKline, 27 of those years working on a malaria vaccine. He launched 14 vaccines and rose to become head of research and development for the entire company.
“Vaccines have always been my first love. That’s what I like best,” he said in an interview with USA TODAY.
Moncef Slaoui Vaccines has always been my first love. quote icon
He retired three years ago and has served on corporate boards and a venture capital firm. He knew all facets of the industry and enjoyed a high reputation in its exclusive circles.
He liked the idea of taking on an almost impossible mission with the prospect of helping humanity – maybe even more so because people thought it was impossible.
Slaoui said he committed himself to co-leading Operation Warp Speed as chief scientific adviser on two conditions: there would be no political interference in his work, and no bureaucracy to hold him back. Both conditions have been met, he said, and science, not politics, has led the way.
Moncef Slaoui, right, tours Temple University Hospital with Chief Medical Officer Tony Reed on November 20. Slaoui is co-director of Operation Warp Speed, the Trump administration’s effort to rapidly develop, manufacture and distribute COVID-19 vaccines and treatments. Temple University Hospital
On the Friday before Thanksgiving, Slaoui visited Temple University Hospital to see what the clinical trial process was like there, how the researchers were able to quickly recruit more than 200 volunteers, and what he could do to help them recruit many more to register.
That morning, six months and four days after he accepted the job, Pfizer and its German partner BioNTech coincidentally declared their vaccine development process complete and applied for permission from the US Food and Drug Administration to open it to the public.
Slaoui expected vaccines against COVID-19 to be very effective — 80% to 90%, he predicted in early summer. The coronavirus that causes COVID-19 is actually very weak, he said. That’s why 8 out of 10 people can shrug it off with limited or no symptoms.
When could a COVID-19 vaccine be approved? FDA Commissioner Stephen Hahn answers frequently asked questions
But the 94 percent efficacy seen with the Pfizer/BioNTech vaccine and another from Moderna is “a dream come true,” he said. “That means we will be able to control this pandemic.”
If people can be persuaded to take it, he added, “We are very, very concerned that people are not taking a vaccine.”
Slaoui came to Temple in part to encourage more people to participate in the study of Johnson & Johnson’s COVID-19 vaccine candidate. He knew that a study with a diverse group of participants would lead to greater acceptance of the vaccine once it became available.
Moncef Slaoui, in a leather jacket, visits Temple University Hospital on November 20. Part of his work has been to recruit a diverse group of clinical trial participants who have helped lead the US COVID-19 vaccine effort. Temple University Hospital
Such on-site visits characterize the hands-on approach he takes to leading vaccine development. He has personally toured at least five other clinical trial sites and a handful of manufacturing facilities.
Slaoui and the Operation Warp Speed team meet every weekday at 8 a.m. — virtually or in person — and spend about five minutes talking about each of the lead vaccine candidates. At 10 a.m. they are doing the same for drugs being developed to treat COVID-19.
They’re called “battle rhythm” meetings, an idea originated by his co-head of Operation Warp Speed, Army General Gus Perna, who heads the military’s 190,000-person logistics and supply chain division.
More: FAA confirms first “bulk air shipment” of Pfizer’s COVID-19 vaccine from Belgium as US prepares for distribution
Now that his part of the job is largely complete, Slaoui is considering stepping down by the end of the year. The focus is on Perna to get the vaccines he helped develop onto the shoulders of millions of Americans.
Everything went surprisingly well, said Slaoui.
Then he superstitiously knocked with both hands on a wooden boardroom table.
The right one for the job
Slaoui did not choose the post of co-leader. He was “not affiliated with this government,” he said, and detested politics.
“I’m disappointed in how mean and unprincipled it’s become,” he said.
But as the Trump administration searched for someone who could undertake unprecedented vaccine development, Slaoui’s name kept popping up.
“When we brought him in for the interview, it was clear that he shared our vision and believed that our ambitious goal of a vaccine was achievable by the end of the year,” said HHS Secretary Azar. “Our faith in him has been rewarded as he has proven invaluable as a scientific advisor to Operation Warp Speed.”
Slaoui was the obvious choice, said Elias Zerhouni, who served as director of the National Institutes of Health during President George W. Bush’s administration and then as president of global research and development at pharmaceutical giant Sanofi.
Elias Zerhouni We couldn’t have found anyone better than Moncef. quote icon
“We couldn’t have found anyone better than Moncef,” he said. “If I think there’s one person who was there, it’s Moncef Slaoui.”
Almost nobody else has developed both vaccines and drugs from the lab to commercialization, understood how to evaluate unproven technologies, is a natural, public service-driven leader and knows how to get things done, Zerhouni said.
Health and Human Affairs Secretary Alex Azar (left) and President Donald Trump recruited Moncef Slaoui, former head of GlaxoSmithKline’s vaccines division, for Operation Warp Speed’s coronavirus vaccine development. Drew Angerer, Getty Images
Levin, the BIO chairman, said he always felt a kindred connection with Slaoui. Levin grew up in South Africa and was disgusted with apartheid; Slaoui in Morocco, against policies that keep the majority of the population trapped in poverty.
“This is a man who stood up for the human condition,” Levin said.
More: Why this Harvard doctor is optimistic the US will overcome COVID-19 despite ‘epidemic of distrust’
Jean-Francois Formela, a friend and successful healthcare venture capitalist, said he was impressed when Slaoui started a venture within GSK.
Many big drug companies have their own venture divisions that invest in early-stage research, but they’re not high-profile because they don’t generate product or money for the company for years, if ever. Slaoui chose to lead the department himself so he could see the interesting work in the field firsthand, Formela said.
Formela said Slaoui was the perfect choice to lead vaccine development efforts because he is a “very, very charismatic, inspirational leader” who can put aside his personal dislike of the administration to help humanity.
Jean-Francois Formela It’s so clear to me, and I suspect most people who know him well, were only on one mission. quote icon
“It’s so clear to me, and I suspect for most people who know him well, that he was just on a mission,” Formela said. “He knew he was one of the few people who could do it. And he chose to do it.”
Political activist to pharmaceutical manager
Slaoui’s journey began during his university days in Belgium in the 1970s when he fell in love with immunology.
He was born in Morocco in 1959 into a family that believed strongly in education.
“Both my father and mother, as their No. 1, had an objective education,” said Slaoui, “which comes with fairness, with values and with helping other people.”
His father opposed the French occupation of the country and spent two years in prison for his politics. After Morocco gained independence in 1956, his father became a successful entrepreneur.
Slaoui had four siblings, one of whom died at the age of 6 months from whooping cough, which could have been prevented with a vaccination. Slaoui wasn’t born, but the loss meant he was raised in a home that understood the value of vaccines.
All three boys ended up in medicine or scientific research; his sister is a professor of French literature.
Slaoui went to university in Belgium and became a political activist, “maybe today he’s seen as a terrorist,” he said with a grin. His aim was to overthrow the monarchy.
He never damaged property or injured anyone, he said, but organized other Moroccan students studying in Belgium and went on two hunger strikes there against the wealth inequality he saw at home.
When he returned to Morocco to visit his ailing mother, he knew he could be targeted by the secret police.
“Because my family was influential, I didn’t end up in jail forever or disappear,” Slaoui said. But it is a “big wake-up call. I said to myself, you can’t help like that because it can end quickly. It’s not very effective.”
He decided to instead make his social impact through health care — including the malaria vaccine he had guarded for decades and one against rotavirus. Both diseases kill hundreds of thousands annually, mostly children.
“It’s much more effective than disappearing into a prison somewhere,” he said.
As a young man, Slaoui decided that healthcare rather than political activism would be his way of making a positive impact on society. Temple University Hospital
Bubbling with unbridled energy, Slaoui has never required more than 4 to 4.5 hours of sleep a night. He wakes up at 3 a.m. every day (4 a.m. on weekends), does a bit of work, then does an hour or two of exercise — solo activities like biking, running, or walking that he could do anywhere in the world where his work took him.
“I have a lot of calls with Europe these hours,” he said. “When I have a call, I will walk quickly, and when I’m done, I will run.”
Exercise lets him release excess energy, gives him time to think about his day, and keeps him cool. “It’s incredibly strong for me,” he said.
He claims not to know how to tie a tie, although he wears one on most of his television appearances. Other days he wears black jeans, sneakers, a leather bomber jacket and a tailored shirt.
He’s never seen “Star Trek,” so his American-born wife had to explain to him what Warp Speed meant. Although some have criticized the name for emphasizing speed over safety, he sees the two as connected rather than contradictory. Racers don’t just want to go fast; You want to get to your destination safely.
“I like cars and speed,” admitted Slaoui, driving to Temple University Hospital in his electric Porsche Taycan. (Prices start at around $100,000.)
He’s only been caught driving once, he said, driving into the office at 5 a.m. thinking more about the presentation he had to give that day to 120,000 GSK workers than obeying the 40-mph speed limit hour to keep.
reaching the finish line
Slaoui has been criticized for being a successful businessman in a government role. He owns approximately $10 million worth of GSK stock, which he has amassed over the course of his career.
One day he plans to retire and live off those dividends, he said, though he admits he’s not the retirement type. He has pledged to donate any money to research the stock appreciates while he works for Operation Warp Speed.
When he was selected for the position, he resigned from the board of Moderna and others who might pose a conflict. He sold all of his shares in the startup, missing out on huge gains in value over the past seven months.
Slaoui takes ethics very seriously. He was upset to learn that although he claimed he only made $1 for his six months in government service, his contract calls for an additional $1,000 – so he made $1,001. He is striving to set the record straight.
The job Operation Warp Speed dramatically changed his life almost overnight.
Not only did he leave the boards, but he also left his job at a venture capital firm looking for companies to invest in.
He moved to Washington from his home in suburban Philadelphia during the weekdays and saw his wife and 8-year-old son only on weekends.
“I miss him and vice versa,” he said, proudly displaying a picture of the boy on his ubiquitous phone. “And my wife, of course.”
Slaoui, who has two adult sons from his first marriage, admits he really enjoys the job.
“I’m having a great time,” he said. As he works on developing the vaccines, he gains insight into many different companies. Normally, “as an industrial person, you only see your stuff. The others are the competitors.”
He loves the “alignment” of the team he works with. They share a common mission: to produce safe and effective vaccines as quickly as possible. The team members bonded very quickly.
“No one has any other agenda,” Slaoui said.
The group’s affiliation with the Department of Defense means companies involved in the work of Operation Warp Speed can get the supplies they need before anyone else.
When a train carrying a key pump needed to make the vaccine for Moderna’s latest study stalled on its tracks, the military installed the pump on an airplane. It arrived on time. Such prioritization allows companies to move faster and scale further than they otherwise would have done, Slaoui said.
Moncef Slaoui We held Moderna by the hand every day. quote icon
“We held Moderna by the hand on a daily basis,” he said.
Moderna’s study recruited well, but not many participants were people of color, who were hit particularly hard by the pandemic. Slaoui understood that if the studies weren’t diverse enough, people of color wouldn’t trust the results to be relevant and wouldn’t feel safe about getting vaccinated.
Operation Warp Speed helped Moderna speed up vaccine development. JOSEPH PREZIOSO/AFP via Getty Images
Slaoui knew the Moderna team from his time on the board. He got annoyed when researchers didn’t listen to the importance of study diversity.
“We ended up yelling at each other,” Slaoui said. “In a respectful but very stressed-out way.”
He convinced the company to slow recruitment of white participants and brought in National Institutes of Health director Dr. Francis Collins, and the director of the National Institute of Allergy and Infectious Diseases, Dr. Anthony Fauci to quickly reach more Blacks and Hispanics in the process.
Leading an operation of this size and scope, Slaoui said, requires very quick decisions and decisions.
“That’s where experience and insight count,” he said. “Otherwise you will make the wrong choice.”
Operation Warp Speed’s scientific adviser Moncef Slaoui says he worries people might be suspicious of a COVID-19 vaccine, even though the vaccine development process has been fairly smooth. Temple University Hospital
Getting Americans to shop
One thing Slaoui cannot control is public opinion.
That’s mainly why he toured the Temple University Hospital clinical trials center on November 20 and Emory University Hospital the week before: to get a feel for the challenges of recruiting into the trials and getting people to participate encourage.
“Thank you for offering your body to science,” Slaoui said to Carlaann Henry, who received the Johnson & Johnson shot at Temple and waited 15 minutes to make sure she wasn’t experiencing any side effects.
“It’s my pleasure and probably my duty,” she told him. “I’m excited to see a trial here in Philadelphia and at Temple.”
He agreed. Outside the hospital, after touring the site, Slaoui called on other Philadelphians to join the trial.
“It’s your civic responsibility to get involved, to help society, to help your country, to help your world, to evaluate vaccine effectiveness,” he said. “This, we are all convinced, will be the only way to get back to our normal lives one day.”
Moncef Slaoui It is your civic responsibility to participate, to help society, to help your country, to help your world to assess vaccine effectiveness. quote icon
Earlier on the same warm November day that Pfizer was asking the FDA for approval of its vaccine, he remarked how remarkable it was that COVID-19 vaccine development had come so far, so quickly.
“That’s one of the great things about America,” Slaoui said. “If you believe and try, you can. It’s just amazing.”
Contact Karen Weintraub at [email protected].
USA TODAY’s health and patient safety reporting is made possible in part by a grant from the Masimo Foundation for Ethics, Innovation and Competition in Healthcare. The Masimo Foundation makes no editorial contribution.
Trump to tap ex-Glaxo executive, U.S. general to spearhead coronavirus vaccine effort
WASHINGTON, May 13 (Reuters) – President Donald Trump is expected to enlist a former GlaxoSmithKline executive and a US general to spearhead the administration’s efforts to develop a coronavirus vaccine under an accelerated timeline officially dubbed ‘Operation Warp Speed ‘ a government official said Wednesday.
Former head of Glaxo’s vaccine division, Moncef Slaoui, will serve as chief adviser on the operation, and US Gen. Gustav Perna will serve as chief operating officer. Trump has previously said he will be the top leader in an effort to develop, test and manufacture a vaccine for the deadly coronavirus that has caused a global pandemic in less time.
Related searches to Moncef Slaoui Bio, Age, Wife, GSK, Coronavirus, Operation Warp Speed, Net worth
Information related to the topic Moncef Slaoui Bio, Age, Wife, GSK, Coronavirus, Operation Warp Speed, Net worth
Here are the search results of the thread Moncef Slaoui Bio, Age, Wife, GSK, Coronavirus, Operation Warp Speed, Net worth from Bing. You can read more if you want.
You have just come across an article on the topic Moncef Slaoui Bio, Age, Wife, GSK, Coronavirus, Operation Warp Speed, Net worth. If you found this article useful, please share it. Thank you very much.